Key result
Rheumatoid arthritis patients had significantly higher serum ANGPTL4 concentrations (363.4 ng/ml) compared to osteoarthritis patients (39.0 ng/ml) and normal controls (45.8 ng/ml).
Observational (n=94)
No
Absolute Event Rate: 363.4% vs 39%
p-value: p=<0.01
ANGPTL4 is over-expressed in the synovium, serum, and synovial fluid of RA patients and correlates with RANKL, suggesting a role in pathological bone resorption.
Serum ANGPTL4 should not guide RA management; leaves open its potential role in bone resorption.
INTRODUCTION: Osteoclasts are responsible for the bone loss associated with rheumatoid arthritis (RA). The secreted adipokine angiopoietin-like 4 (ANGPTL4) specifically increases osteoclast-mediated bone resorption. We have investigated expression of ANGPTL4 and its regulatory transcription factor, hypoxia-inducible factor-1 alpha (HIF-1α), in osteoclasts and other cells within rheumatoid synovium. We have also examined whether circulating levels of ANGPTL4 differ in RA patients compared with that in normal controls or patients with osteoarthritis (OA). RESULTS: Immunohistochemical analysis revealed that bone-apposing osteoclasts within the rheumatoid synovium express both ANGPTL4 and HIF-1α. ANGPTL4 was also strongly expressed in synovial lining cells, endothelial cells, stromal cells, CD68+ macrophages and plasma cells within RA synovium. Little ANGPTL4 was evident in normal synovial tissue. This reflected the over-expression of HIF-1α in rheumatoid versus normal synovial tissue. The concentration of ANGPTL4 was higher in both the serum and the synovial fluid of RA patients than in patients with OA or normal controls. High serum ANGPTL4 associated with elevated levels of the serum marker of bone resorption, receptor activator for nuclear factor κB ligand (RANKL). CONCLUSIONS: Over-expression of ANGPTL4 in multiple cell types within the rheumatoid synovium potentially provides a local pool of ANGPTL4 to stimulate osteoclast-mediated bone resorption in RA. Additionally, correlation of high serum ANGPTL4 with circulating RANKL suggests that ANGPTL4 may represent a novel marker for bone destruction in RA.
No takes yet. Share an insight, caveat, or question.
Swales et al. (2014) conducted an observational in Rheumatoid Arthritis (n=94). Rheumatoid arthritis vs. Osteoarthritis and normal controls was evaluated on Serum ANGPTL4 concentration (ng/ml) (p=<0.01). Rheumatoid arthritis patients had significantly higher serum ANGPTL4 concentrations (363.4 ng/ml) compared to osteoarthritis patients (39.0 ng/ml) and normal controls (45.8 ng/ml).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: